| Variablea |
Chi Square (X2) |
Correlation Coefficientb (r) |
P-value |
| Clinical Information |
|
|
|
| Hypertension |
7.6 |
|
0.01 |
| CHD Risk Level by FRS |
3.1 |
|
0.08 |
| HIV-specific Information |
|
|
|
| Duration HIV infection (years) |
|
-0.2 |
0.003 |
| Total months NRTI use |
|
-0.2 |
0.001 |
| Abacavir |
2.9 |
|
0.09 |
| Didanosine |
13.9 |
|
0.0002 |
| Laboratory Results |
|
|
|
| Triglyceride level (mg/dL) |
|
-0.3 |
<0.0001 |
| Fasting glucose (mg/dL) |
|
-0.1 |
0.05 |
| hsCRP (mg/dL) |
|
-0.2 |
0.003 |
| HDL (mg/dL) |
|
0.2 |
0.0005 |
| Weight and Fat Measurements |
|
|
|
| BMI (kg/m2) |
|
-0.2 |
0.01 |
| Waist circumference (cm) |
|
-0.1 |
0.06 |
| Waist/hip ratio (cm) |
|
-0.1 |
0.06 |
| Percent body fat |
|
-0.1 |
0.09 |
| Physician Visual Assessment |
|
|
|
| Lipohypertrophy |
9.2 |
|
0.002 |
a Table shows only the variables significantly correlated with adiponectin. All variables were inversely correlated with adiponectin, except for HDL in which higher HDL levels were correlated with higher adiponectin levels
b Spearman correlation coefficient |
